These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10024823)

  • 1. [Prevention of dyslipidemia--the foremost challenge in the management of diabetes].
    Smith U; Taskinen MR
    Lakartidningen; 1999 Jan; 96(4):334-6. PubMed ID: 10024823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.
    Lewis GF
    Can J Cardiol; 1995 May; 11 Suppl C():24C-28C. PubMed ID: 7750045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids in type 2 diabetes.
    Laakso M
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia in type 2 diabetes.
    Krauss RM; Siri PW
    Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).
    Meyers CD; McCarren M; Wong ND; Abraira C; Duckworth WC; Kashyap ML;
    Am J Cardiol; 2006 Jul; 98(1):63-5. PubMed ID: 16784922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin therapy for the treatment of diabetic dyslipidemia.
    Haffner SM
    Diabetes Metab Res Rev; 2003; 19(4):280-7. PubMed ID: 12879405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.
    Pastromas S; Terzi AB; Tousoulis D; Koulouris S
    Int J Cardiol; 2008 May; 126(1):3-12. PubMed ID: 17689745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?
    Kendall DM
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):27-48. PubMed ID: 15752920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2].
    Wolffenbuttel BH; Huijberts MS
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):761-5. PubMed ID: 11346911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD
    Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.